Steven M Grunberg
Affiliation: University of Vermont
- Incidence of chemotherapy-induced nausea and emesis after modern antiemeticsSteven M Grunberg
Department of Medicine, University of Vermont, Burlington, Vermont 05401, USA
Cancer 100:2261-8. 2004..They also assessed whether physicians and nurses accurately recognized the incidence of acute and delayed CINV in their own practices...
- Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the artSteven M Grunberg
Division of Hematology Oncology, University of Vermont College of Medicine, 89 Beaumont Avenue, Given Building E214, Burlington, VT 05405, USA
Support Care Cancer 19:S43-7. 2011..Additional efforts will be necessary to understand mechanisms of nausea and to identify optimal remedies...
- Emerging treatments in chemotherapy-induced nausea and vomitingSteven M Grunberg
The University of Vermont College of Medicine, Burlington, Vermont, USA
Clin Adv Hematol Oncol 11:1-18; quiz 2 p following 18. 2013..The second-generation 5-HT3 receptor palonosetron has a unique pharmacology that makes it especially effective at preventing delayed emesis...
- Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-contrSteven M Grunberg
University of Vermont, Burlington, VT 05405, USA
Lancet Oncol 10:549-58. 2009....
- Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?Steven M Grunberg
Fletcher Allen Health Care, UHC Campus St Joseph 3400, 1 South Prospect Street, Burlington, VT 05401, USA
J Support Oncol 2:1-10, inside back cover; quiz 11. 2004..In addition, new approaches to treatment, such as neurokinin-1 antagonists, acupressure, and acustimulation, will be discussed...
- Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapySteven M Grunberg
Division of Hematology Oncology, Vermont Cancer Center, 89 Beaumont Avenue Given Bldg E214, Burlington, VT 05405, USA
Support Care Cancer 17:589-94. 2009..The present study evaluated a more convenient single-day three-drug antiemetic regimen for patients receiving moderately emetogenic chemotherapy...
- Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an updateSteven M Grunberg
University of Vermont, Burlington, Vermont 05401, USA
Support Care Cancer 13:80-4. 2005..A separate four-level classification system for emetogenicity of oral antineoplastic agents, which are often given over an extended period of time, is also proposed...
- Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancerSteven M Grunberg
Division of Hematology Oncology, University of Vermont, Burlington, Vermont, USA
Cancer Invest 23:392-8. 2005..The non-platin chemotherapy doublet of paclitaxel and vinorelbine given on this convenient 3-day schedule is worthy of further investigation in the treatment of non-small cell lung cancer...
- Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningiomaSteven M Grunberg
Division of Hematology Oncology, University of Vermont College of Medicine, Burlington, Vermont, USA
Cancer Invest 24:727-33. 2006..Meningioma is a benign central nervous system tumor that is often progesterone-but not estrogen-receptor positive, making long-term antiprogestational therapy a logical treatment strategy...
- Obstacles to the implementation of antiemetic guidelinesSteven M Grunberg
Division of Hematology Oncology, University of Vermont College of Medicine, Burlington, VT 05405, USA
J Natl Compr Canc Netw 7:601-5. 2009..The relationship between these factors and the scientific basis of antiemetic guidelines must be considered to achieve optimal results and compliance...
- Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesisSteven M Grunberg
Division of Hematology Oncology, University of Vermont, Burlington, Vermont 05401, USA
Expert Opin Pharmacother 4:2297-303. 2003..Palonosetron provides a convenience advantage if multiple-day 5-HT(3)-receptor antagonist therapy is anticipated and is a unique addition to the antiemetic armamentarium...
- Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility scoreSteven M Grunberg
Division of Hematology Oncology, Fletcher Allen Healthcare, University of Vermont, UHC Campus St Joseph 3400, 1 South Prospect Street, Burlington, VT 05401, USA
Support Care Cancer 10:624-9. 2002..46. This is a reasonable negative surrogate anchor and is being used in a current Cancer and Leukemia Group B (CALGB) study...
- Optimal use of antiemetics in the outpatient settingSteven M Grunberg
University of Vermont, Burlington, USA
Oncology (Williston Park) 16:1401-7; discussion 1407-8, 1412. 2002..Investigation of additional potentially important neurotransmitter receptors, such as the opioid and cannabinoid receptors, may result in further improvements in antiemetic control and quality of life in coming years...
- New developments in the management of chemotherapy-induced emesis: do they impact on existing guidelines?Steven M Grunberg
Department of Medicine, University of Vermont, Burlington, Vermont, USA
Oncology (Williston Park) 18:15-9. 2004....
- Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kineticsMichael J Toth
Department of Medicine, University of Vermont, College of Medicine, Burlington, VT, USA
J Appl Physiol (1985) 114:858-68. 2013..Collectively, our results suggest reductions in myofilament protein function as a potential molecular mechanism contributing to muscle weakness and physical disability in human cancer...
- Aerorespiratory tract cancer in older patientsAqeel A Gillani
Division of Hematology Oncology, The University of Vermont, UHC Campus, St Joseph 3400, 1 South Prospect Street, Burlington, VT 05401, USA
Semin Oncol 31:220-33. 2004..Although prevention remains the mainstay of management of aero-respiratory cancers, carefully planned treatment can result in therapeutic benefit with maintenance of quality of life...
- Malignant mesothelioma following thoracic radiotherapy for lung cancerSabrina M Witherby
Department of Medicine, University of Vermont College of Medicine, Vermont Cancer Center, 89 Beaumont Avenue, Given E 214, Burlington, VT 05405, USA
Lung Cancer 57:410-3. 2007..Secondary malignancies such as mesothelioma should be considered in patients who develop unexplained symptoms even long after treatment of a primary tumor...
- First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsLecia V Sequist
Massachusetts General Hospital Cancer Center, 32 Fruit St, Yawkey Suite 7B, Boston, MA 02114, USA
J Clin Oncol 26:2442-9. 2008..The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms...
- American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006Mark G Kris
American Society of Clinical Oncology, Alexandria, VA, USA
J Clin Oncol 24:2932-47. 2006..The literature review focused on published randomized controlled trials, and systematic reviews and meta-analyses of published phase II and phase III randomized controlled trials...
- Management of patients receiving long-term treatment with mifepristoneIrving M Spitz
Institute of Hormone Research, Jerusalem, Israel
Fertil Steril 84:1719-26. 2005..To determine clinical side effects and biochemical and hematological abnormalities in patients with nonresectable meningioma on long-term mifepristone (RU 486) therapy...
- Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomitingSant P Chawla
Century City Hospital, Los Angeles, California 90067, USA
Cancer 97:2290-300. 2003..The current study sought to define the most appropriate dose regimen of oral aprepitant...
- The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study GrPaul J Hesketh
Caritas St Elizabeth s Medical Center, Brighton, MA 02135 2997, USA
J Clin Oncol 21:4112-9. 2003....
- Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statementLawrence H Einhorn
Division of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN 46202 5289, USA
Support Care Cancer 13:112-6. 2005..However, the results do not appear as successful as for highly emetic standard-dose chemotherapy...
- New directions in supportive careSteven M Grunberg
Support Care Cancer 13:135-7. 2005..Even symptoms such as fatigue and overall outlook may be defined in terms of appropriate enzymatic pathways. Evaluation and application of these advances in basic science are leading directly to new directions in supportive care...
- Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyDavid G Warr
Princess Margaret Hospital, Medical Oncology, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
J Clin Oncol 23:2822-30. 2005..This is the first study in which the NK(1)-receptor antagonist, aprepitant (APR), was evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy...
- The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trialsDavid G Warr
Princess Margaret Hospital, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
Eur J Cancer 41:1278-85. 2005..In addition, even among patients who had emesis or needed rescue therapy, aprepitant was associated with a lower frequency of these events compared with the control regimen...
- Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyJørn Herrstedt
Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark
Cancer 104:1548-55. 2005..An aprepitant (APR) regimen was evaluated for prevention of nausea and emesis due to moderately emetogenic chemotherapy (MEC) over multiple cycles...
- Antiemetic guidelines: creating a more practical treatment approachJim M Koeller
University of Texas Health Science Center at San Antonio, Pharmacotherapy MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
Support Care Cancer 10:519-22. 2002..Although this document alone may not solve all the challenges with appropriate antiemetic management, it will hopefully prove to be a step in the right direction...
- Birth and re-birthSteven M Grunberg
Support Care Cancer 16:979. 2008